514 reports of this reaction
2.0% of all ALISKIREN HEMIFUMARATE reports
#8 most reported adverse reaction
DYSPNOEA is the #8 most commonly reported adverse reaction for ALISKIREN HEMIFUMARATE, manufactured by LXO US Inc.. There are 514 FDA adverse event reports linking ALISKIREN HEMIFUMARATE to DYSPNOEA. This represents approximately 2.0% of all 26,137 adverse event reports for this drug.
Patients taking ALISKIREN HEMIFUMARATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for ALISKIREN HEMIFUMARATE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for ALISKIREN HEMIFUMARATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 514 FDA reports for ALISKIREN HEMIFUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.0% of all adverse event reports for ALISKIREN HEMIFUMARATE, making it a notable side effect.
If you experience dyspnoea while taking ALISKIREN HEMIFUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.